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A total of 53 national cystic ﬁbrosis (CF) patient registry studies published between July 2008 and November 2011 have been reviewed,
focusing on the following topics: CF epidemiology, nutrition, microbiology, clinical complications, factors inﬂuencing diagnosis and lung disease,
effects of socioeconomic status, therapeutic strategy evaluation, clinical trial methodology.
The studies describe the clinical characteristics of CF patients, the incidence and prevalence of disease and role of gender gap, as well as the
inﬂuence of socioeconomic status and environmental factors on clinical outcomes, covering a variety of countries and ethnic groups. Original
observations describe patients as they get older, with special reference to the adult presentation of CF and long-term survival. Methodological
aspects are discussed, covering the design of clinical trials, survival analysis, auxometry, measures of quality of life, follow up of lung disease,
predictability of disease progression and life expectancy. Microbiology studies have investigated the role of selected pathogens, such as
Burkholderia species and MRSA. Pulmonary exacerbations are discussed both as a factor inﬂuencing morbidity and an endpoint in clinical trials.
Finally, some studies give insights on complications, such as CF-related diabetes and hemoptysis, and emerging problems, such as chronic
nephropathy.
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Patient registries are powerful tools designed to advance
knowledge on disease progression and management. They
provide systematically collected data that disclose patterns in
disease diagnosis, treatment and outcomes over time [1].
Registries can provide valuable insights into the safety and/or
effectiveness of an intervention, and establish the efficiency,
timeliness, quality, and patient-centeredness of a health system
aimed at the care of a complex and resource-consuming disease,
such as CF. The usefulness and applicability of registry data rely
heavily on the quality of the data analysis plan and on the ability
of the users to interpret the results. Users have to bear in mind any
quantitative and/or qualitative shortcomings of the data that could
be sources of bias. This requires close teamwork among
clinicians, epidemiologists, statisticians, study coordinators, and
others involved in the design, conduct, and interpretation of the
results of registry-derived studies.
Starting from the late 1960s, several national registries of
cystic fibrosis (CF) patients have been set up. At first they
collected mainly demographic data; subsequently clinical and
outcome data were added to verify the clinical effectiveness and
safety of therapies and to measure quality of care. Quite a large
number of papers report registry data. We have already provided
reviews of this literature; the last update was in June 2008 [2–4].
Since then, several papers based on national registry data have
been published worldwide. This article reviews them in detail.2. Methods
The procedure of literature analysis, and inclusion and
exclusion criteria have been described previously [2–4]. A
search in Pubmed and Embase up to the cut-off date of November
30, 2011 was carried out including also papers only published
online. We included primary studies that used data collected by
national patient registries. Cohort studies not based on registry
data were excluded, as well as those based on local or non CF
registries, and those that used the registry data only as controls for
other epidemiological and clinical studies or for RCTrecruitment. We also excluded reviews, comments, editorials
and letters concerning CF registries; articles in which registries
were only quoted; annual reports from registry organizations;
duplications of already published papers.
3. Results and discussion
A total of 53 studies were found and analyzed (Table 1)
using a dedicated grid [2]. The main topics considered are:1. Demographics
2. Incidence/prevalence
3. Survival/gender gap
4. Genetics
5. Nutritional status and growth
6. Microbiology
7. Complications
8. Factors influencing diagnosis
9. Factors influencing lung disease
10. Socioeconomic status/quality of life
11. Therapeutic strategy evaluation
12. Clinical trial methodology3.1. Demographics
Two papers from the European CF Demographic Registry
(ECFDR) analyzed data from European countries. McCormick et
al. [5] presented results from the largest multinational study in CF
(29,025 patients). The authors modeled demographic indicators,
based upon data collected in 2003 from 35 countries (12 European
Union (EU) members and 23 non-EU European countries) to
estimate the size of the CF population if non-EU countries had had
the same resources available for patients as EU countries did. The
median age in EU countries (17.0 years) was higher than in
non-EU countries (12.1 years), with a difference of 4.9 years
(95% CI 4.4–5.1). The proportions of patients in the older
age-groups were smaller in non-EU than in EU countries even
before the age of 20 years, with striking differences in the
proportion of patients aged 35–44 years. In non EU-countries the
Table 1
Studies included in the review.
Year Registry Topic 1st author Ref
Demographics
2010 EU Comparative demographics in Europe McCormick J 5
2010 EU CF across Europe: analysis of demographic data Mehta G 7
2011 Australia CF in Australia Bell SC 9
Prevalence
2008 EU The prevalence of CF in the European Union Farrell PM 10
Survival
2009 CFF Morbidity and mortality in the US Hispanic Danieli Watts K 11
2011 CFF-RoI Methods to compare CF median survival internationally Jackson AD 12
2011 CFF-RoI A parametric model for CF survivorship Jackson AD 13
2011 Italy Gender gap in survival in the pediatric age Viviani L 14
Genetics
2010 French D1152H CFTR mutation Burgel PR 18
Nutritional status and growth
2008 CFF Classification of malnutrition in cystic fibrosis Lai JH 20
2009 Germany Ideal body weight as measure for nutritional failure Hirche TO 21
2010 CFF Genetic potential when evaluating stature Zhang Z 22
Microbiology
2008 CFF Burkholderia infection and lung transplantation Murray S 27
2009 CFF Respiratory Microbiology in the US, 1995 to 2005 Razvi S 30
2008 ESCF MRSA and pulmonary function Sawicki GS 33
2009 CFF MRSA and FEV1 Decline Dasenbrook EC 34
2010 CFF MRSA and Survival Dasenbrook EC 36
Complications
2008 UK Genetic and Epidemiology of CF‐Related Diabetes Adler AI 39
2010 UK Diabetes and Mortality in CF‐Related Diabetes Chamnan P 40
2011 UK Hyperglycemia and Death in CF-Related Diabetes. Adler AL 41
2008 Israeli Hemoptysis Efrati O 43
2011 CFF Chronic Kidney Disease in Adults with CF Quon BS 44
Factors influencing diagnosis
2010 RoI Delayed CF presentation in children Jackson A 45
2010 CFF Adult Presentation of CF Keating CL 46
2010 CFF Symptom progression in young CF patients Yan J 47
2011 CFF Effect of strategies of newborn screening Sanders DB 48
Factors influencing lung disease
2008 ESCF Trends in the clinical characteristics in U.S. CF patient VanDevanter DR 49
2007 ESCF Risk factors for rate of decline in FEV1 in CF Konstan MW 50
2010 ESCF Pulmonary outcome prediction (POP) tools VanDevanter DR 51
2010 ESCF Year-to-year changes in lung function Liou TG 52
2010 CFF Pulmonary function after pulmonary exacerbation Sanders DB 55
2010 CFF Pulmonary exacerbations and FEV(1) decline Sanders DB 56
2010 CFF Influenza-associated CF pulmonary exacerbations. Ortiz JR 57
2010 CFF Predictors of influenza vaccination Ortiz JR 58
2010 Canada Risk of hospitalization among females with CF Stephenson A 59
2010 Various Disease progression in CF long-term survivors Nick JA 60
2011 CFF Acquisition of PA infection Ji S 61
2011 Various Environmental factors and lung disease Collaco JM 62
Socio-economic status — quality of life
2009 ESCF Socioeconomic status and use of chronic therapies Schechter MS 63
2011 ESCF Socioeconomic Status and Antibiotic Treatment Schechter MS 64
2010 ESCF Socioeconomic Status, Race, Ethnicity Quittner AL 65
2011 Canada Socioeconomic status and risk of hospitalization Stephenson A 66
2011 ESCF Health-related quality of life in cystic fibrosis Sawicki GS 67
2010 Germany Anxiety and depression in CF Goldbeck L 68
2011 ESCF Health-related quality of life in cystic fibrosis Quittner AL 69
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Table 1 (continued)
Year Registry Topic 1st author Ref.
Therapeutic strategy evaluation
2008 ESCF Inhaled corticosteroid and lung function decline Ren CL 70
2010 Belgium Inhaled corticosteroids and lung function decline De Boeck K 71
2010 ESCF Trends in the use of routine therapies in cystic fibrosis Konstan MW 75
2008 ESCF Inhaled antibiotic use Moskovitz SM 76
2011 ESCF Use of dornase alfa and rate of FEV(1) decline Konstan MW 77
2011 CFF Mortality and use of tobramycin inhalation solution Sawicki GS 79
Clinical trial methodology
2010 ESCF Design and powering of CF clinical trials Konstan MW 80
2011 ESCF Design and powering of CF clinical trials Vandevanter DR 82
CFF: United States Cystic Fibrosis Foundation; ESCF: United States Epidemiologic Study of Cystic Fibrosis; EU: European Union; UK: United Kingdom; RoI:
Republic of Ireland.
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cohorts (0–9 years vs. 10–19 years age groups) whereas in EU
countries it increased by 24%, suggesting poor survival in non-EU
countries. The authors estimated that if the non-EU countries had
comparable resources to the EU countries, the size of the CF
population would increase by 84%, particularly in the ≥10 years
age bracket. The decreased number of CF patients in non-EU
countries is more likely to be due to reduced availability of
specialist drugs, equipment, and trained multidisciplinary staff,
rather than lower CF gene frequency, greater disease severity, or
poorer treatment adherence than in EU countries. Moreover, the
low number of diagnoses in children younger than 1 year in
non-EU countries is an important piece of information, probably
due to the death of infants with unrecognized CF. Underdiagnosis
and inequality in access to health care have been described as
major drivers for increased mortality in CF [6]. The Authors of the
European study believe that both factors are likely to affect the
non-EU and new (after 2004) EU countries, and urge political
institutions to address the issue as a matter of urgency.
European cross-sectional demography data were subsequently
updated and re-examined in a country-specific analysis by the
same group of authors [7]. Out of 29,095 patients, 57% were
children (b18 years of age) and 53% were male. The age profile
showed relative paucity of children b5 years of age, possibly
because of underdiagnosis. These data are not surprising,
considering that only a minority of European countries had
implemented a neonatal screening (NBS) program for CF at birth
at the time the data were collected. As previously reported [5], a
significantly faster decline in the 25–30 and 30–35 age groups was
evident. The paucity of patients in the adult age groups most likely
reflects differences in outcome of inadequate nutrition in
childhood, when pancreatic enzyme substitution was unavailable
in some countries in the early 1980s. According to previous
comments [2], properly targeted and CF-specific high calorie
nutrition, which is relatively inexpensive for any EUmember state,
should be the first step towards improving CF outcome. NBS
would permit early introduction of such simple measures, and then
CF survival might be expected to dramatically improve andtherefore be readily measurable. A gender gap is noticeable:
overall, males significantly outnumber females and the excess
number of young CF males is consistent across age groups, but
becomes even more pronounced as age increases. Relative stability
of the numbers of male versus female patients should be carefully
checked in the future as an outcome standard to evaluate whether
NBS and early, modern treatment are effective in prolonging life
and possibly compensate for the apparent disadvantage of females
in all examined countries.
EuroCareCF and the European CF-Registry working group
have now joined, founding the new ECFS Patient Registry [8].
This is a new database recording 47 variables, which are selected
and defined per patient per year. In 2009 it had already collected
data of 20,204 patients from 16 countries; at present it is extending
participation to both national registries and individual CF centers.
Bell et al. [9] describe a cross-sectional analysis of data from
the Australian Cystic Fibrosis Data Registry (ACFDR) for 2009.
It included 2986 patients (median age 17.6 years, 48% female,
49% adults), with an estimated coverage of about 90% of all CF
patients. The incidence of CF, averaged over 5 years of ACFDR
data to 2008, was 1 in 2986 (95% CI, 2735–3288) births. From
1979 to 2005 the mean age at death increased from 12.2 years to
27.9 years for males and from 14.8 to 25.3 years for females.
3.2. Incidence/prevalence
In addition to the article cited just above [9], a paper by Farrell
[10] addressed the topic of prevalence and incidence in the 27
countries included in the European Union (EU) since 2007. Mean
global prevalence was 0.737 per 10,000, similar to the prevalence
in the United States population (0.797 per 10,000). Besides
pointing out some technical doubts about calculation of variance
and the resulting interval, including homogenous prevalences and
excluding outliers, we suggest that the comparison of prevalence
between EU and US should be cautious because of the greater
uniformity and quality of data from the US CF Foundation
Registry (CFFR); only a few national registries in Europe (such as
those of UK, France, Germany, Italy) may achieve similar quality
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selected centers and not from national registries. We think that well
established registries should be used for such comparisons. The
author raises this problem, stressing that information available
from the UK provides an estimate that suggests that there may be
up to 14% more CF patients in EU countries.
3.3. Survival/gender gap
The topic of survival was addressed in 4 studies, focusing
either on survival and mortality or on the methodology to
evaluate the related data.
Danieli Watts et al. [11] performed a study on patients from
the US CFFR to compare the prevalence of risk factors known to
be associated with morbidity and mortality between Hispanic and
non-Hispanic CF populations. They observed that the Hispanic
patients had an increased prevalence of early clinical diagnosis,
presumably due to earlier onset of symptoms, acquisition of
Pseudomonas aeruginosa (PA) at a younger age, worse
pulmonary function tests (PFT), increased prevalence of liver
disease and indicators of low socioeconomic status (SES) (i.e.
low median income, state insurance, low maternal education),
whereas CF-related diabetes (CFRD) was less frequent. These
data confirmed the results of previous studies examined in our
previous review [2]. However, mortality did not differ between
healthy non-Hispanic and Hispanic Caucasian infants and was
lower in people of Hispanic ethnicity than in the general US
population. Therefore, the higher risk of mortality in Hispanic CF
patients than in non-Hispanic patients cannot be explained by
ethnicity alone and additional environmental and socio-economic
influences must be involved. Possible limitations of the study are
the vague identification of Hispanic ethnicity, the non specific
reference values for PFT and growth (a selection bias in the event
that a disproportionate number of Hispanic patients are cared for
outside CF centers or do not consent to participate in the CFFR),
the use of unadjusted odds ratios (OR) and the absence of
multivariate analysis.
Data from US CFF and Irish Registries were used by Jackson
et al. in 2 studies [12,13]. The 1st study [12] compared median
predicted survival (MPS) and median age at death (MAD) in CF
patients from the US and the Republic of Ireland (RoI), with the
aim of evaluating whether these two parameters were good
measures of CF survival and a useful way to compare small
registries with large ones. The study showed that in both
countries MAD increased from 1986 to 2008 (US: from 20 to
26 years; RoI: from 11 to 24 years), whereas MPS in the same
period increased from 25 years in 1986 to 37 years in 2008 in US
and from 23 to 34 years in RoI. The authors warned that the
between‐country comparison might be inappropriate, because,
particularly in small registries, the instability of annual mortality
rates can be misleading. In these cases, analysis of longitudinal
outcomes provides better insights into survival trends.
In the 2nd paper [13] the same authors validate a parametric
model to project survival estimates beyond observed survivorship
data following a short follow-up period. Analyzing a CFFR
dataset, four model structures, each with a distinct underlying
survivorship function for fitting observed data into parametricmodels, were deemed suitable for examination: exponential,
Weibull, log-logistic and log-normal. AWeibull model containing
gender and birth cohort as the main effects fitted the US data best,
excluding patients who died before their 1st birthday (high
mortality rates during the 1st year of life led to a poor fit). The
model was then applied to the RoI cohort. The MPS calculated
with the birth cohort lifetable in US patients (surviving their 1st
birthday) born between 1980 and 1984 was 37.8 years for males
(95% confidence interval [CI] 36.2–39.3) and 31.5 for females
(95%CI 30.4–32.6); and 50.9 (95%CI 48.0–53.8) and 42.4 (95%
CI 40.2–44.5) years, respectively, for males and females born
between 1985 and 1994. For RoI patients, MPS was 32.3 (95%CI
27.1–37.5) and 24.7 (95% CI 21.3–28.1) years, respectively, for
males and females born between 1980 and 1984 and 51.1 (95%CI
38.8–63.3) and 39 years (95% CI 30.8–47.1) for those born
between 1985 and 1994. Irish data, because of the smaller sample
size, have very wide 95% CI. Model‐predicted median survival
estimates were then calculated and their estimates converged to
the true values as the length of follow up increased. The authors
claimed that this model could provide an adequate estimate of
median survival even in cohorts followed-up for short periods and
experiencing continued improvement in survival, such as the CF
population. It is important to note the presence of a strong gender
gap in CF survival, with the females having a negative impact, as
previously reported [2] and also mentioned in [9].
The gender gap in CF survival is the topic of the study by
Viviani et al. [14], from the Italian registry. In this cohort, among
patients born after January 1, 1988 and followed up until
December 31, 2004, higher female mortality was not observed:
the hazard ratio (HR) of death of females, adjusted for presence of
symptoms or meconium ileus at diagnosis, F508del mutation and
age at diagnosis, was higher than for males, but the difference was
not statistically significant (1.29; 95%CI 0.6–2.76). However, the
number of registered deaths was small (74 patients, 35 males) so a
rather low power of the test might have softened the difference.
The authors do not exclude, however, that differences in mortality
would ensue after adolescence. It would be interesting to analyze
the survival patterns of those patients after puberty.
The issues about the gender gap in cystic fibrosis are still open
and subject to debate. Data from the Scandinavian CF Study
Consortium [15] highlighted gender differences but did not find
any significant differences in key clinical parameters. However, the
data suggested that males were at an advantage, as there were more
males in the adult population and females required more intensive
treatment with antibiotics, macrolides and steroids and were
hospitalized for longer periods of time. One single US center [16]
observed that earlier Pa infection, particularly before 5 years of
age, was strongly associated with increased odds of severe lung
disease and that this association was stronger in females than in
males (adjusted OR for severe lung disease in females vs. males=
9, both compared to the same sex-matched group). Finally, a recent
report from the UK Office for National Statistics confirmed that in
England and Wales CF females continue to be more likely die at a
younger median age than males [17].
Further studies, especially in cohorts of patients diagnosed
early with CF by NBS, should establish whether modern
treatment, introduced as soon as possible, is effective in
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in females or not.
3.4. Genetics
One study dealt with genetic aspects of CF. Burgel et al. [18]
described 42 patients from the French registry carrying the
D1152H CFTR mutation, classified as a class IV mutation with
residual CFTR function and considered either as a true CF‐causing
mutation or a mutation associated with CFTR-related disorders
[19]. These patients were characterized bymild pulmonary disease,
male infertility, low sweat chloride, infrequent PA colonization and
low prevalence of pancreatic insufficiency. All subjects had
prolonged survival.
3.5. Nutritional status and growth
Three studies, deriving from the CFF and German registries,
addressed this issue [20–22]. Classification of malnutrition is a
subject up for discussion in CF [3]. Lai et al. [20] applied the
evidence based nutrition classification recommended by CFF in
2005, disregarding the percentage of ideal body weight (%IBW)
and setting the goal of bodymass index (BMI) at 50th percentile in
children (b20 years old). The new classification rule resulted in a
6% reduction in the nutritional failure rate in this cohort; 57% of
patients were below the goal of the 50th percentile. Moreover, the
authors show that misclassification of nutritional failure due to
%IBW overestimates malnutrition in tall patients and underesti-
mates it in short ones.
This observation is reinforced by the report from the German
registry [21], which postulated that the main reason for this
discrepancy is that the %IBW method disregards the statistical
principle of regression to the mean. The paper shows that the key
assumption of %IBW (ideal weight-for-age is exactly at the same
percentile ranking as height-for-age) would be valid only if the
individual's height was close to the reference median. When
stature deviates from the median of the reference population the
increments of height-for-age and weight-for-age percentiles are
not the same. Consequently, the %IBW method systematically
overestimates malnutrition in taller patients and underestimates it
in shorter-than-average individuals, like CF patients.
Therefore, the use of an inappropriate indicator could be
misleading also in judging center‐specific quality improvement
programs and benchmarking. In this context, anthropometric
measures should be integrated by other markers of malnutrition,
such as abnormal status of fat-soluble vitamins and essential fatty
acids [20].
The methodological aspects of the evaluation of growth in CF
patients are the subject of the study by Zhang et al. [22] on US data
related to children with documented parental heights. Eighty % of
the CF children were shorter than the mean height of their parents
These data are in agreement with several previous observations [3],
but the stature of US parents of the CF patients, unlike Italians [23],
was normal. However, the data were collected using different
methods: US parental heights were only self‐reported while the
Italian ones were measured directly. Moreover, the authors assess
the agreement between the classic CFF target height method,widely used in anthropometry [24], and the Himes method [25],
based on statistical modeling of age-specific relationships between
mean parental heights and children's heights. The two methods are
quite different in the evaluation of short stature, whose prevalence
was 9% with CFF method compared with 22% with the Himes
method. On the other hand, the observation that, whatever method
is used, the overall prevalence of short stature in this cohort is
underestimated without the adjustment for genetic potential
(parental stature), strongly supports the importance of accounting
for parental heights when evaluating stature in children with CF.
Moreover, the Himes adjusted height, unlike the unadjusted one,
was significantly associated with lung function. The CFF method
is simple, but less accurate than the Himes method, which, vice
versa, is complicated and inconvenient to use in routine practice.
Further research is needed to develop a better method that retains
both simplicity and accuracy.
3.6. Microbiology
Respiratory tract infections remain the primary cause of
morbidity and mortality in CF patients. A better understanding
of the microbial epidemiology of CF should provide further
opportunities to improve treatment strategies and refine infection
control measures [26].
Murray et al. [27] studied the impact of Burkholderia cepacia
complex (BCC) infection on survival before and after lung
transplantation (LT) in patients derived fromCFFR. Infectionwith
different BCC species was not associated with significantly higher
mortality rates in transplant candidates. Among transplant re-
cipients infected with B. cenocepacia, only those infected with
non-epidemic strains had significantly greater post-transplant
mortality than uninfected patients (HR 2.52; 95% CI 1.04–6.12).
The same was true for transplant recipients infected with
Burkholderia gladioli, who had significantly greater post-
transplant mortality than uninfected patients (HR 2.23; 95%
CI, 1.05–4.74). On the other hand, hazards were similar
between uninfected transplant recipients and those infected with
Burkholderia multivorans. BCC infection has been associated
with increased risk of mortality both before and after LT in CF
patients [2,3] so that many centers have considered BCC infection
to be an absolute contraindication to LT. In this study the role of
the identification of distinct bacterial species within BCC resulted
to be relevant. Previous observations [28,29] on LT recipient CF
patients confirmed the detrimental role of B. cenocepacia versus
other BCC species (mostly B. multivorans). With the limitations
of retrospective data, this multivariate analysis showed that the
risk of poor outcome after LT varies among BCC species, being
higher for patients infected by some strains of B. cenocepacia and
B. gladioli, while no increased risk was evident for patients
infected by B. multivorans as compared to uninfected ones. These
findings should be taken into account in evaluating LT candidates.
Razvi et al. [30] studied the epidemiology of bacterial
pathogens in US CF patients from 1995 to 2005. During the
study period the annual prevalence of PA significantly declined
from 60.4% to 56.5%, particularly in children b18 years, whose
incidence of Methicillin‐susceptible Staphylococcus aureus
(MSSA), on the other hand, significantly increased (from 21.7%
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(from 37% to 52.4%). Also Methicillin‐resistant SA (MRSA)
prevalence increased from 0.1% in 1995 to 17.2% in 2005, notably
in adolescents. Increased prevalence was reported forHaemophilus
influentiae, Stenotrophomonas maltophilia (SM) and Alcaligenes
xylosoxidans (AX). Finally, prevalence and incidence of BCC
declined. Also a recent analysis in the UK showed significant
increases in the prevalence of infections due to SM and AX
between 1985 and 2005 [31]. As in the US, the proportion of
patients reported to be infected with BCC decreased but, in
contrast, no significant changes in the proportion of patients
infected with PA or SA were found during this interval. The
reasons for these apparent changes in microbial epidemiology in
CF are not entirely clear. It is possible that changes in patient care
and demographics have played a role in altering infection
frequencies. The aggressive use of antibiotics targeting PA in
both chronic suppressive and early eradication strategies may be
contributing to declines in the prevalence of infection due to this
species. The increasing median age of patients with CF may be
providing new opportunities for infection by SM, AX and other
species. Better adherence to rigorous infection control measures
may have resulted in a decrease in the incidences of PA and certain
BCC species. However, these data must be interpreted with
caution. Discrepancies between data reported to the CFF Registry
and data collected by a separate active surveillance program at the
same institution have been described [32]. A further example is
provided by MRSA, the prevalence of which has dramatically
increased among US CF patients during the past decade.
Nevertheless, the calculation of the statistical significance of the
changes in MRSA prevalence rates based on the rate of 0.1%
reported to the CFF Patient Registry in 1995 is problematic insofar
as a data field for MRSA was not included in the registry at that
time.
The impact of MRSA on CF patients is now debated. Three
studies deal with this matter. Sawicky et al. [33] analyzed data
from the US Epidemiologic Study of Cystic Fibrosis (ESCF),
previously evaluated cross-sectionally [4]. This longitudinal study
found that MRSA was a marker for more aggressive antibiotic
therapy in CF patients, and might be associated with greater
disease severity, but was not associated with an increased rate of
decline in lung function over 2 years. At the same time,
Dasenbrook et al. [34] described, on CFFR data, that persistent
MRSA infection was associated with a more rapid decline of lung
function in children. Discrepancies between these reports were
commented on by the authors [35], stressing the differences in the
analyses (longitudinal vs. registry data, transient vs. persistent
infection, different sample sizes, and the appropriate choice of
Sawicki [33] of comparing patients who acquired MRSA with
those who did not). All the authors agree that only a prospective,
longitudinal study on MRSA in CF will fully provide clinicians
with adequate knowledge.
The role of MRSA was further examined in another paper by
Dasenbrook et al. [36], where CFFR data were studied to
determine whether MRSA infection was associated with worse
survival rates. The mortality rate was 18.3 deaths (95% CI,
17.5–19.1) per 1000 patient-years without MRSA and 27.7
deaths (95% CI, 25.3–30.4) per 1000 patient-years withMRSA. The unadjusted hazard ratio associated with MRSA
was 1.47 (95% CI, 1.32–1.62). After adjustment for time-
varying covariates associated with severity of illness, MRSA
remained associated with a higher, albeit moderate, risk of
death (1.27; 95% CI, 1.11–1.45).
Key issues related to the role of MRSA in CF continue to be
debated. Whether MRSA actually increases the risk of death of CF
patients or is only secondarily associated with poorer clinical
conditions is a matter for further targeted studies.
In conclusion, chronically colonized CF airways represent a
surprisingly complex and diverse ecosystem. The precise
contributions of different microorganisms to patient morbidity,
and especially the importance of inter-specific interactions, remain
largely unclear [37]. Co-infections involving different species of
bacteria, or bacteria, fungi and viruses, are common and probably
the norm, and co-infecting species may interact, both synergisti-
cally and antagonistically [38].3.7. ComplicationsIn a large study of over 5000 patients and 15,000 person-years,
with a median follow-up of 2.67 years, Adler et al. [39] observed
526 individuals with CF-Related Diabetes (CFRD) and estimated
that the annual incidence of CFRD was 3.5%. The incidence rose
with age, was higher in females up to age 40, and declined after
age 40 for both men and women. The authors identified the main
risk factors for CFRD to be class I and II CFTR mutations, female
gender, liver dysfunction, steroid use and poor pulmonary
function. The same authors [40] showed that individuals with
CFRD had considerably higher age‐adjusted mortality rates
compared to those without diabetes (4.2 [95% CI 3.4–5.1] vs.
1.5 [1.3–1.7] per 100 person‐years, respectively). With the
univariate analyses, CFRDwas associatedwith a fourfold increase
in risk of death as compared to patients without CFRD (HR 4.04,
95% CI 3.23–5.07). In multivariate modeling CFRD was
associated with a 31% increase in risk of death independent of
other complications of CF, with the females having a HR 1.71
compared to males (95% CI 1.36–2.14). Finally, the UK authors
[41] observed that HBA1c value ≥6.5% was associated with a
threefold increased risk of death, independently of other clinical
factors.
These studies confirm the previous ones [4] in terms of impact
of CFRD on morbidity and mortality, particularly in women. This
knowledge induced clinicians to detect CFRD early, starting from
childhood and to introduce management with insulin therapy, so
that previously noted gender differences in mortality are possibly
going to disappear, and the gap in mortality between CF patients
with and without diabetes may narrow considerably [42].
Efrati et al. [43] described Israeli CF patients with hemoptysis.
In this study, even massive hemoptysis did not seem to be a major
risk factor for mortality. Bronchial artery embolization was
associated with a high and immediate rate of success in controlling
symptoms, but did not change the course of the underlying
disease. CFRD and liver cirrhosis were frequently associated with
hemoptysis.
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chronic kidney disease (CKD), defined as estimated glomerular
filtration rate (eGFR)b60 ml/min/1.73 m2 in two consecutive
registry years in the adult CF population from CFFR (the 1st study
on this topic). CKD annual prevalence was 2.3% during the study
period, doubling with every 10‐year increase in age. CF adults
diagnosed with CKD were older than those without (39.0 vs.
25.8 years), more likely to be female (53.2% vs. 45.6%), and more
likely to be diagnosed with CFRD requiring insulin (33.3% vs.
13.3%) in the year prior to entry in the cohort. CFRD requiring
insulin was the main risk factor for CKD (1–4 years of CFRD
versus no CFRD: HR=2.40, 95% CI 1.74–3.32;≥5 years: HR=
4.56, 95% CI 2.84–7.31). Pulmonary exacerbations (PE) did not
significantly increase the risk of CKD. This result is surprising, in
view of the widespread use of intravenous aminoglycosides to treat
pulmonary exacerbations. Presumably, the relatively short expo-
sure period failed to detect an increase in risk due to limited
cumulative drug exposure.3.8. Factors influencing diagnosisJackson et al. [45] reported data from the registry of the
Republic of Ireland, where, in the absence of NBS, the diagnosis of
CF was based exclusively on symptoms. Family history (without
symptoms) led to a diagnosis in a greater proportion of patients
(15.1%). This may partially reflect the high incidence of disease
(1:1353 live births) in a country where pregnancy termination is
illegal, and mean family size is rather large. Gender was not
significantly associated with a delayed presentation: in the study
population, the median age at diagnosis of males was greater than
the median age of females (6.0 vs.4.4 months, not significant),
independently of the clinical picture at diagnosis. These findings
are in contrast with an earlier Irish study [4].
Keating et al. [46] provided a detailed analysis of adult
(N18 years of age) presentation of CF from CFFR data. Adults
showed the commonly described CF respiratory features (PA
infection and reduced lung function), but had lower sweat
chloride values and lower frequency of F508del mutation with a
higher proportion of the class IV or V CFTRmutations. Analysis
of gender differences at the time of diagnosis did not disclose any
differences with regard to lung function, microbiology or
genotype. An important limitation of this study is the lack of
male infertility and recurrent pancreatitis as presenting symp-
toms, data not collected in CFFR.
Yan et al. [47] studied CFFR data, proposing analyses of
symptom progression (the prevalence of ever positive and currently
positive patients for PA infection in the lungs) using temporal
process regressions as an alternative to proportional hazardmodels.
The authors not only showed that infants diagnosed by NBS had a
lower prevalence of PA infection than patients diagnosed by
symptoms, but also that the benefit diminishes with age.
Sanders et al. [48] used the CFFR to identify the CF infants
born between 2001 and 2008 and diagnosed by NBS, comparing
ages at diagnosis, genotyping, sweat test, and first visit to a CF
center between states that used serial immunoreactive trypsinogen
(IRT/IRT system) levels and states that used IRT and DNAanalysis (IRT/DNA). The IRT/DNA states diagnosed and treated
infants with CF at younger ages than the IRT/IRT ones. Whatever
the methodology used, quality should be improved in order to
shorten the time of diagnosis and treatment. Incidentally, this
study stresses the need for quality improvements in data entry into
CF registries when the CF community is using these valuable
resources.3.9. Factors influencing CF lung disease
VanDevanter et al. [49] demonstrated, on ESCF data, that the
prevalence of signs and symptoms of lung disease in the US
population of patients with CF decreased from 1995 to 2005, with
parallel improvements in pulmonary function. Differences in the
absolute and relative magnitude of changes in prevalence of cough,
sputum production, crackles, and wheezing over the study period
differed both among age groups and among variables. Cough
improvement occurred in the younger patients and reduction in
sputum production was most notable in the middle age groups,
which were also characterized by the greatest improvement in lung
function. These data could be the results of several factors, such as
the availability of new drugs (i.e. rhDNase, inhaled tobramycin)
and/or the increasingly aggressive management and preventive use
of various therapies. The decreasing prevalence of symptoms could
reduce the magnitude of possible improvement in the respiratory
domain of health-related quality of life measurements; this
possibility should be taken into account in the design of therapeutic
studies.
Konstan et al. characterized the rate of FEV1 decline in
children and adolescents with CF who participated in the ESCF
(50*). A multivariate model was developed, which enabled the
estimation of the annualized change in FEV1 over the next
4 years in individual CF patients aged 6–17 years, using a
multivariate equation that weighted the contribution of various
risk factors (e.g., weight for age, presence of physical findings,
infection status). High baseline FEV1 and persistent crackles
were significant independent risk factors for FEV1 decline across
all age groups. Female gender, PA infection, low weight-for-age,
daily sputum production, wheezing, sinusitis, pulmonary exac-
erbations treated with intravenous antibiotics, abnormal liver test
results, and pancreatic insufficiency were also identified as
independent risk factors in some age groups.
VanDevanter et al. [51], using ESCF data, extended the work
explained in [50] by developing a simple clinical scoring tool to
estimate annualized change in FEV1% predicted over the near
future for CF patients aged 6–17 years, which was called
POP6–17 (“PulmonaryOutcome Prediction”).Moreover, a similar
approach was used to develop a second POP tool (POP2–5) to
estimate FEV1% predicted at age 6 years for CF patients aged
2–5 years. The POP tools, weighting the contribution of each
variable for pulmonary outcome, may help the standardization of
patient management and could lead to more rigorous intervention
for previously unrecognized higher risk patients. Maybe this tool
could be used with caution by clinicians to communicate the
relative probability of future lung disease progression and
outcomes to patients with CF and their families.
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“population changes” with “individual changes”: data related to
the aggregated population (age-specific medians) showed the
presence of an initial period of modest decline in FEV1%,
followed by a steeper decline from early adolescence to early
adulthood; subsequently, another period of modest decline
around age 30 was evident, after which FEV1% appeared to be
stable. Evaluation of FEV1% for consecutive years of age showed
that at most ages the individual year-to-year change was a drop of
1 to 3 FEV1% predicted points. The mean and median of
individual year-to-year changes were always negative, with
larger declines until about age 15 and smaller declines through
adulthood up to age 45. Through age 15, the change in median
FEV1%, based on aggregated population data, was in agreement
with individual data for year-to-year change. In contrast, the
change in median FEV1% based on the population data showed
higher variability after age 15, but approximated zero in patients
over age 30. These observations regarding year-to-year individ-
ual trends in lung function for a wide range of patient ages
provided information that was relevant for decision making in
clinical practice. Identification of the patients with the greatest
declines in pulmonary function may pinpoint those most in need
of additional attention.
Recognizing that some individuals have more aggressive CF
phenotypes and predicting their risk of immediate lung disease
progression is a critical step in managing pneumopathy and
extending the life expectancy of CF patients. FEV1 measure-
ments are important surrogate measures of disease progression
and survival in CF, but it is important that static disease staging,
referring to the degree (severe, moderate, mild) of pathologic
deterioration of the lung is integrated by the dynamic notion of
disease severity, better assessed using decline in FEV1 [53]. This
is true both in the clinical setting and for the design of therapeutic
clinical trials.
Pulmonary exacerbations (PE) have been considered as high
risk factors for morbidity [50] and are constantly present as an
important factor in survivorship models in CF [2,4,54]. Efforts
towards the prevention and the earlier identification of PE
would have definite benefits for patients with CF, at all ages.
Sanders et al. studied problems associated with PE in CF, using
data from CFFR [55,56]. In the 1st study [55] the authors showed
that 25% of PE treated with IV antibiotics resulted in failure to
return to FEV1 levels achieved within the last 6 months before
treatment. Failure to return to baseline pulmonary function was
associated with several factors known to be associated with lower
pulmonary function in CF, namely female sex, pancreatic
insufficiency, poor nutrition, Medicaid insurance status, persistent
infection with PA, BCC, or MRSA and ABPA. Patients with
higher risk for failing to return to baseline need earlier identification
of PE to begin prompt treatment before a large fall in FEV1 occurs
or before a longer time has elapsed since baseline assessment. In
the 2nd study [56], the authors test the hypothesis that patients who
had more frequent PEs during a defined 1-year baseline period
(year 2003) would experience a greater rate of FEV1 decline over
the subsequent 3 years. In fact, the study showed that there was a
strong association between the number of PEs and subsequent
decline in lung function, both in adults, having three or more PEsper year, or in children with any number of PEs. Whether this
relationship is the result of failure to recover following an acute PE,
or an accelerated pulmonary function decline is uncertain.
Another point of view about PE is seasonality. Ortiz et al. [57]
examined CFFR data, suggesting that a substantial proportion of
morbidity in CF is associated with the influenza season. Adjusted
ORs comparing PE during the influenza season to the summer
season baseline were 1.07 (95% CI 1.05–1.10) in adults and 1.08
(95%CI 1.05–1.12) in children. In a subsequent analysis, the effect
of the influenza season on individuals with ≥4 PE was
investigated. In these sicker patients the overall influenza season
PE incidence rate was nearly to an order of magnitude greater than
in the full cohort. Although further studies to determine any causal
link between influenza and CF PE are necessary, influenza
vaccination is still considered the best way to avoid infection and
its complications, even though no definitive evidence is available
for CF patients. The same authors examined CFFR data to better
understand the differences between those receiving and those not
receiving the influenza vaccination [58]. Although vaccination
rates were high at all ages, significantly lower rates of vaccine
receipt were associated with lack of health insurance, non‐white
ethnicity, use of oxygen therapy during the previous year and lower
number of clinic visits per year. Efforts should focus on the patients
with lower rates of vaccine receipt, ensuring their vaccination and
encouraging patients to meet the CFF goal of four or more clinic
visits per year.
Stephenson et al. [59] assessed whether PEs determine higher
rates of hospitalization in females with respect to males in
Canadian CF patients from Ontario. The adjusted rate ratio (RR)
of annual hospitalizations comparing females vs. males was 1.37
(95% CI 1.10–1.71) in younger patients and 1.30 (95% CI 1.06–
1.59) in adults. It is unclear whether the association of female
gender with high rates of hospitalization for PE is another aspect
of the “gender gap” or there are other possible reasons explaining
these results: different patterns of prescribing medications,
hormonal influences, higher rate of CFRD or different attitudes
to hospital admissions could be involved.
Nick et al. [60] studied different databases (Colorado CF
Database, CFFR and Multiple Cause of Death Index) evaluating
outcomes in a cohort of long-term survivors (40 years or older).
The cohort was subdivided into two groups, namely patients with
childhood diagnosis [CD], before 10 years of age, and patients
with adult diagnosis [AD], after 18 years of age. The impact of
gender on progression of disease, patient survival, cause of death,
the setting in which these patients receive their care, the rate of
clinic attendance, and the response to treatment of newly diagnosed
adult patients was assessed. The long-term CD survivors had more
severe CFTR genotypes and phenotypes than the long-term AD
survivors. However, after the age of 40 years the rate of FEV1
decline and death from respiratory complications was not different
between these cohorts. CD females were less likely to reach age
40 years and experienced faster FEV1 declines, and had survival
disadvantage compared with males. On the other hand, most AD
patients were females, who experienced equal FEV1 decline, but
survived longer than males, despite being older at diagnosis. Most
AD patients were followed in a setting of care other than CF
centers, and with increasing age a smaller percentage of CF deaths
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CF center care achieved significant and sustained FEV1 improve-
ment from the time of diagnosis over a period of 4 years.
This report brings out several important results: the prevalence
of pancreatic insufficiency and of high-risk CFTR genotypes is
higher in CD patients than in AD individuals, but the overall
severity of lung disease, in terms of FEV1 decline and death from
respiratory complications, is similar between the two cohorts,
showing that AD patients do not actually have mild disease, but
rather just as serious, albeit delayed, lung disease as in CD
patients. Moreover, the issues related to the relationship between
morbidity/mortality and gender are numerous. In this study a
gender gap to the detriment of females is apparent in CD cohort,
whereas the opposite is true in the AD cohort. This original
observation warrants further investigation to determine whether
the preponderance of AD females and the survival advantage of
females diagnosed as adults are due to underrepresentation of AD
males with mild CF lung disease. A number of gender-related
factors could contribute to an increased frequency of AD in
females, including greater persistence in seeking the diagnosis
and overall greater use of the health care system. In addition, a
bias may exist against referral of males presenting with
congenital bilateral absence of the vas deferens (CBAVD) to
CF centers, resulting in an underrepresentation of males in
databases of AD CF patients.
Another point of interest is that many long-term survivors of CF
are not seen at the CF centers. This regards above all the older AD
cohort. However, when patients are assessed in terms of response
to care, newly diagnosed AD patients exhibit sustained FEV1
improvement in response to the CF center care. This finding
supports the idea that the CF center care, typically representing a
more aggressive approach to airway clearance and pathogen-
specific antibiotic treatment of airway infection, is of benefit to the
AD cohort. Finally, studies of AD patients are critical, as the true
penetrance and complete phenotype associated with a vast number
of rare CFTR mutations can be conclusively defined only later in
life. This knowledge may be very useful to physicians attempting
to guide patients and families when genetic risk factors for CF are
identified in symptomatic or even asymptomatic children or young
adults. In fact, data from this report indicate that patients with the
non-classic form of the disease who are diagnosed early and treated
aggressively may be expected to live a full life span, but when
diagnosis and/or treatment is delayed, the morbidity of non-classic
CF may be severe. These findings support the conclusion that
asymptomatic or oligosymptomatic individuals who are found to
have a genetic background for CF, should be regularly monitored
for disease progression at the CF centers, even when they have
mild disease.
Ji et al. [61] proposed the use of quantile regression in survival
analysis, to overcome the issue of double censoring, which occurs
in biomedical research when an outcome of interest is subject to
both left censoring and right censoring. The quantile regression
method assesses how covariates impact various quantiles of time
to first PA infection without restricting their effects to be constant
in contrast with the traditional Cox regression. In patients with CF
(data from CFFR), out of 12,818 diagnosed between 1986 and
2000, 3343 (26.1%) patients had PA infection at study entry (leftcensored) and 2213 (17.3%) patients had no PA infection as
documented by December 2005 (right censored). The analyses
showed earlier acquisition of the first PA infection in females and
an association between more recent diagnosis and shorter time to
first PA infection. A possible explanation is that cultures are
performed much more often in these patients; the increased
frequency of cultures may shorten the time needed to detect PA
infection in patients with late onset of such infection as compared
to those who experience the first PA infection at a younger age.
Prior studies from CF Registries have demonstrated associa-
tions between lung function and local environmental factors,
including second hand smoke exposure and air pollution [4].
Collaco et al. [62] studied the data from the US CF Twin and
Sibling Study, the CFFR, the ACFDR and from Australia/New
Zealand Bronchoalveolar Lavage Trial to evaluate whether
geographic factors were associated with the presence of respiratory
pathogens in CF or with variation in lung function, as well as the
relative impact of geographic factors compared to other environ-
mental factors (demographic or household) in multivariate
analyzes. All datasets examined showed independently that the
presence of PA was associated with warmer temperatures.
Moreover, warmer temperatures and public insurance were
associated with lower lung function. These findings suggest that
accounting for temperature should be considered in the design of
both epidemiological studies of infection and/or lung function and
of clinical trials that encompass broad geographic areas. Also
geographymay need to be considered when the performance of CF
care centers is compared.
3.10. Socioeconomic status and quality of life
A cross-sectional analysis of data on patients of age b18 years
from the ESCF, conducted by Schechter et al. [63], showed
that disease severity (measured by weight-for-age percentile
and percent predicted FEV1) was inversely correlated with 3
socioeconomic status (SES) measures (median household income
by zip code, maternal educational attainment and state insurance
coverage), but health outcome disparities were not explained by
different use of health services or prescription of chronic therapy.
The same authors evaluated, in a similar dataset, whether SES
influences the likelihood of antibiotic treatment of pulmonary
exacerbations (PE) in patients with CF [64]. Again, SES had little
effect on treatment for PE with any antibiotics, but intravenous
antibiotics were prescribed more frequently to patients with lower
SES, suggesting that healthcare providers, recognizing that patients
with low SES could have worse disease outcomes, tend to treat
these patients more aggressively. Both studies, even in the presence
of a relationship between SES and disease severity, found no
evidence that SES-related disparities in CF outcome were caused
by differences in care, either in the treatment of PE or the use of
health services and prescription of chronic therapies.
These authors performed a further cross-sectional study using
data obtained from the ESCF, to examine the effects of SES on
Health Related Quality Of Life (HRQOL) in patients with CF from
childhood through adulthood [65]. Low SES was associated with
significantly lower CF Questionnaire-Revised (CFQ-R, a disease-
specific HRQOL measure) scores related to children, parents, and
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severity and SES status, African-American and Hispanic patients
reported worse emotional and social functioning. The CFQ-R
showed effects that were consistent with those observed for
patients' clinical outcomes and disclosed effects in the psychoso-
cial domain that had not been previously identified (e.g., concerns
about body image, social and role functioning). From this
perspective, interventions focusing on better nutrition, adherence
to treatment regimens, and greater social support appear to be
critical.
The influence of SES on CF was examined also by Canadian
authors [66]. Stephenson et al. found no significant relationship
between SES and annual risk of respiratory-related hospitalization
in a large cohort of pediatric and adult CF subjects. Moreover, no
relationship between nutritional status and SES was found.
However, better lung function was seen to be associated with
higher incomes.
The US and Canadian studies differed in several aspects: US
studies were cross-sectional over 1-year period, used different
measures of SES, included only children and excluded patients
with missing data. In contrast, the Canadian study examined adult
and pediatric patients longitudinally over a maximum of 10 years
and under a substantially different health care system that is not
dependent on the ability to pay.
In conclusion, recent studies evaluating relationships between
SES and CF confirmed the association of greater disease
morbidity and mortality [17] with low SES, but found no
evidence that SES-related disparities in CF outcome were caused
by differences in care, either in the treatment of PE or in the use of
chronic therapies and outpatient monitoring. Probably, several
other mechanisms, variably related to SES disparities, could be of
greater importance, such as disease self-management, health
behaviors (including cigarette smoking, and second hand smoke
exposure), exposure to psychological stress and environmental
pollutants [2–4].
Sawicki et al. [67] used ESCF records to examine the
relationship between changes in health status and changes in
CFQ-R scores. Significant associations were found between
changes in health status, particularly objective indicators of
respiratory and nutritional health and treatment complexity with
significant changes in HRQOL during the same time period. In
addition, increases in weight were also associated with improve-
ments in Respiratory Symptom scores, highlighting the important
link between nutritional and respiratory health in CF. CFQ-R
proved to be sensitive to longitudinal changes in health status
across age groups. This is encouraging for clinicians who are
considering the option of implementing HRQOL measures in
routine CF clinical care, as well as for researchers using patient-
reported outcomes in clinical trials.
Goldbeck et al. [68] used data from the German registry to
evaluate mental health in CF patients. Anxiety is an important
issue for a large proportion of CF patients, particularly in
adults and females. The risk of depression increased as
impairment in lung function increased. The high rates of
psychological symptoms in the study and the association of
mental well-being with the adherence to treatment indicate the
strong need for psychosocial care for patients with CF, withspecial attention paid to psychological symptoms during
critical phases of the disease (e.g., diagnosis of CFRD,
occurrence of hemoptysis/pneumothorax, or decision to go
on the transplant list).
Quittner et al. [69] evaluated the psychometric properties of
CFQ-R in a sample of patients from the ESCF. The CFQ-R
consistently discriminated between patients seen for sick-versus-
well visits, and among stages of disease severity based on lung
function. CF women reported worse HRQOL than men on scales
not related to body image and weight. Strong parent–child
agreement was found on scales measuring observable behaviors
(respiratory symptoms). Convergence between CFQ-R scales and
health outcomes provided evidence of construct validity.3.11. Therapeutic strategy evaluation
Ren et al. [70] used ESCF data to evaluate the therapeutic effect
of inhaled corticosteroids (ICS) on lung function in CF children by
examining the changes in the rate of decline of FEV1 before and
after initiation of ICS. They found that the mean annual decline in
predicted FEV1 in ICS patients changed from −1.52 to −0.44%,
compared with −1.01 to −1.44% in the control group. Patients
treated with ICS showed a drop in height Z-scores and an
increased use of hypoglycemic agents.
A similar analysis based on data from the Belgian CF Registry
was conducted by De Boeck et al. [71]. Yearly % predicted
decline in FEV1 was −1.07% lower during years with ICS use as
compared to years without ICS use, but subgroup analysis showed
that this effect was mainly observed in children aged 6‐12 years
(−2.56%FEV1 decline; p=0.0003), whereas no effect was seen in
the older age groups, regardless of PA colonization. No significant
effect was shown on growth, but in the 6–12 year group a small
decrease occurred; insulin use was not significantly increased in
ICS users. The findings of these last two studies [70,71] are
important because they disagree with a recent randomized
controlled trial (RCT) [72] that, however, was not designed or
powered to detect the effect of ICS on the rate of change in percent
predicted FEV1. Registry data, because of their retrospective
analysis, are less suitable to determine causality, and are usually
subject to several pitfalls (i.e. selection and information bias),
although several methods for controlling confounding variables
are available [70,73] in order to partly overcome this limit. In any
case, the results of the registry-based studies are never easy to
compare with those of RCT [74] and both groups of authors agree
that this clinical issue needs to be addressed by a properly
designed RCT.
Konstan et al. [75], extending a previous study from the ESCF,
already commented on [4] and reported changes in the use of
routine CF therapies from 1995 to 2005: use of several therapies
increased, including airway clearance, inhaled bronchodilators,
rhDNase, ICS, inhaled antibiotics, oral nutritional supplements
and insulin/oral hypoglycemic agents. Some therapies not tracked
in 1995 were widely used in 2005, including oral macrolide
antibiotics, leukotriene inhibitors/antagonists and inhaled hyper-
tonic saline. In general, therapies were more frequently used by
older patients and those with lower FEV1.
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prevalence of inhaled antibiotic use (either tobramycin or colistin)
increased from 1996 to 2005. This increase was associated with
markers of severity, such as PA infection and impaired lung
function, although the relatively high rate of chronic inhaled
tobramycin use among patients without chronic PA infection is
quite surprising. Moreover, no data are available to distinguish
between maintenance and eradication usage.
Konstan et al. [77] add further knowledge about the therapeutic
role of rhDNase in CF. Previous analysis showed that patients
benefit slightly from this drug, whose tolerability and safety
profile is good in all age groups [4]. This study confirmed that
initiating rhDNase therapy led to acute improvement in FEV1 and
that constant use of the drug was associated with some
improvement in the annual rate of decline in FEV1 over a 2-year
period, confirming results achieved by RCTs [78].
Sawicki et al. [79], using CFFR data, studied the association
between the use of tobramycin inhaled solution (TIS) andmortality
in patients with CF and chronic PA infection. TIS was associated
with a 21% reduction in the odds of subsequent annual mortality
(adjusted OR: 0.79, 95% CI 0.72–0.88, pb0.001). Adjusted
mortality rates for patients reporting TIS use in all versus none of
the follow-up years were 1.3% versus 2.1% at 2 years, 5.2% versus
8.0% at 5 years, and 9.9% versus 15.0% at 10 years. An opposite
association was found in an earlier analysis of the CFFR previously
commented on [4]. The earlier study used only the first 2 years of
data collection following approval in 1997 of TIS and was
presented as an example of selection bias by indication, because
TIS was initially used mainly by patients with more severe disease.
In Sawicki's study TIS use was at first associated with OR for
subsequent-year mortality of 1.58 (95% CI 1.12–2.23) among
patients with index year 1998, but changed to OR 0.73 (95% CI
0.51–1.04) among patients with index year 2000 or later,
leveraging an additional 9 years of CFFR data. By finding a
positive association between TIS use and reduced mortality, as
might be expected, given the established effects of TIS on the
improvement of lung function and reduction in exacerbations, this
study suggests that the incorporation of more data can help
overcome the limitations discussed in the earlier analysis.
3.12. Clinical trial methodology
Konstan et al. [80] used ESCF data to evaluate important
factors in the design and powering of CF studies that use “rate of
FEV1 decline” as an efficacy endpoint, instead of the sustained
improvement in FEV1, which is easier to achieve in studies, but
not necessarily linked to a decreased rate of FEV1 decline [81]. It
was shown that increasing study duration and exclusion of lower
risk patients (e.g., no PA infection) both substantially reduced the
requirements. Studies of 1.5 years in duration appeared feasible,
provided that investigators account for the beneficial effects of
subject inclusion/exclusion based on risk factors in power
estimates. In our opinion, this study offers an interesting and
original proposal for improving the power of a study and the
significance of the results when designing clinical trials.
With a similar aim, namely evaluating the reduction in
pulmonary exacerbations (PE) as an efficacy endpoint for CFclinical studies, VanDevanter et al. [82] estimated the PE rates for
ESCF patients stratified by several risk factors. At all ages,
decreased FEV1, female sex, PE history, and PA culture history
were associated with increased treatment for PE. Sample sizes
required to attain 80% power to detect PE reductions ranging from
20% to 80% in 1:1 randomized studies lasting 3 to 12 months were
determined. Moreover, the authors stated that detecting an impact
on PE rate in some subpopulations (e.g., subjects with early lung
disease) may prove problematic due to sample size requirements.
4. Conclusions
Registries boost research in CF and underpin the hypotheses
development and priority setting for future clinical research. They
are a valid complement to controlled, randomized clinical trials in
the assessment of outcomes in medical practice; inclusion and
exclusion criteria are not restrictive, provided that diagnostic
procedures for placing patients in the registry are sound and
consistent. On the other hand, the use of information from registries
requires awareness of possible incompleteness of records, of the
quality of data in terms of consistency and updating, and of the
arbitrary nature of certain operational definitions. Nowadays, more
than 160 registry-based analyses have been published, and the
ongoing European CF Registry [8] is an exciting resource that
could add further knowledge, similar to that deriving from US
registries on large numbers of patients. Common efforts designed
to record high quality data should clarify further aspects of CF and
help to promote further improvements in care and, consequently, in
quality of life and survival of CF patients.
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